Trial · NCT03010176
Results by group37
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 37
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Part 1: Percentage of Participants Who Experienced a Dose-limiting Toxicity (DLT) Per Common Terminology Criteria for Adverse Events, Version 4.0 (CTCAE 4.0) | Part 1 Arm 1: Ulevostinag (Cut/Subcut Lesions) | 15.1 | 80% Confidence Interval 6.6 to 21.8 | Percentage of participants | |
| Part 1: Percentage of Participants Who Experienced a Dose-limiting Toxicity (DLT) Per Common Terminology Criteria for Adverse Events, Version 4.0 (CTCAE 4.0) | Part 1 Arm 2: Ulevostinag+Pembro (Cut/Subcut Lesions) | 10.4 | 80% Confidence Interval 5.3 to 14.5 | Percentage of participants | |
| Part 1: Percentage of Participants Who Experienced a Dose-limiting Toxicity (DLT) Per Common Terminology Criteria for Adverse Events, Version 4.0 (CTCAE 4.0) | Part 1 Arm 3: Ulevostinag+Pembro (Visceral Lesions) | 0 | 80% Confidence Interval 0.0 to 6.0 | Percentage of participants | |
| Parts 1 and 2: Number of Participants Who Experienced One or More Adverse Events (AEs) | Part 1 Arm 1: Ulevostinag (Cut/Subcut Lesions) | 32 | Participants | ||
| Parts 1 and 2: Number of Participants Who Experienced One or More Adverse Events (AEs) | Part 1 Arm 2: Ulevostinag+Pembro (Cut/Subcut Lesions) | 66 | Participants | ||
| Parts 1 and 2: Number of Participants Who Experienced One or More Adverse Events (AEs) | Part 1 Arm 3: Ulevostinag+Pembro (Visceral Lesions) | 26 | Participants | ||
| Parts 1 and 2: Number of Participants Who Experienced One or More Adverse Events (AEs) | Part 2 Cohort A: HNSCC Anti-PD-1/PD-L1 Refractory | 21 | Participants | ||
| Parts 1 and 2: Number of Participants Who Experienced One or More Adverse Events (AEs) | Part 2 Cohort B: Anti-PD-1/PD-L1 TrT-Naïve or Refractory TNBC | 25 | Participants | ||
| Parts 1 and 2: Number of Participants Who Discontinued Study Drug Due to an AE | Part 1 Arm 1: Ulevostinag (Cut/Subcut Lesions) | 3 | Participants | ||
| Parts 1 and 2: Number of Participants Who Discontinued Study Drug Due to an AE | Part 1 Arm 2: Ulevostinag+Pembro (Cut/Subcut Lesions) | 7 | Participants | ||
| Parts 1 and 2: Number of Participants Who Discontinued Study Drug Due to an AE | Part 1 Arm 3: Ulevostinag+Pembro (Visceral Lesions) | 3 | Participants | ||
| Parts 1 and 2: Number of Participants Who Discontinued Study Drug Due to an AE | Part 2 Cohort A: HNSCC Anti-PD-1/PD-L1 Refractory | 3 | Participants | ||
| Parts 1 and 2: Number of Participants Who Discontinued Study Drug Due to an AE | Part 2 Cohort B: Anti-PD-1/PD-L1 TrT-Naïve or Refractory TNBC | 2 | Participants | ||
| Parts 1 and 2: Ulevostinag Area Under the Plasma Drug Concentration-Time Curve From Time Zero to 24 Hours (AUC0-24) | Part 1 Arm 1: Ulevostinag (Cut/Subcut Lesions) | 8.62 | Full Range 0.31 to 34.67 | nM*hr | |
| Parts 1 and 2: Ulevostinag Area Under the Plasma Drug Concentration-Time Curve From Time Zero to 24 Hours (AUC0-24) | Part 1 Arm 2: Ulevostinag+Pembro (Cut/Subcut Lesions) | 6.59 | Full Range 0.57 to 41.43 | nM*hr | |
| Parts 1 and 2: Ulevostinag Area Under the Plasma Drug Concentration-Time Curve From Time Zero to 24 Hours (AUC0-24) | Part 1 Arm 3: Ulevostinag+Pembro (Visceral Lesions) | 5.88 | Full Range 0.11 to 24.3 | nM*hr | |
| Parts 1 and 2: Ulevostinag Area Under the Plasma Drug Concentration-Time Curve From Time Zero to 24 Hours (AUC0-24) | Part 2 Cohort A: HNSCC Anti-PD-1/PD-L1 Refractory | 6.24 | Full Range 1.78 to 12.4 | nM*hr | |
| Parts 1 and 2: Ulevostinag Area Under the Plasma Drug Concentration-Time Curve From Time Zero to 24 Hours (AUC0-24) | Part 2 Cohort B: Anti-PD-1/PD-L1 TrT-Naïve or Refractory TNBC | 7.98 | Full Range 2.43 to 13.48 | nM*hr | |
| Parts 1 and 2: Ulevostinag Minimum Plasma Concentration (Cmin) | Part 1 Arm 1: Ulevostinag (Cut/Subcut Lesions) | 0.18 | Full Range 0.06 to 3.09 | ng/mL | |
| Parts 1 and 2: Ulevostinag Minimum Plasma Concentration (Cmin) | Part 1 Arm 2: Ulevostinag+Pembro (Cut/Subcut Lesions) | 0.12 | Full Range 0.05 to 1.16 | ng/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03010176/results